How Much Do Doctors Make? [Salary by Specialty 2025]

Image
Facebook Facebook Email or phone Password Forgot account? Create new account You're Temporarily Blocked You're Temporarily Blocked It looks like you were misusing this feature by going too fast. You've been temporarily blocked from using it. Back English (US) Español Français (France) 中文(简体) العربية Português (Brasil) Italiano 한국어 Deutsch हिन्दी 日本語 Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Meta AI more content Instagram Threads Voting Information Center Privacy Policy Consumer Health Privacy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Settings Activity log Meta © 2026 Invalid Access Key! Invalid Access Key!

Emergent Biosolutions completes acquisition of PaxVax

Emergent BioSolutions (NYSE:) has its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases.

With the closing of this transaction, Emergent acquires two marketed vaccines – Vivotif (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever, and Vaxchora (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera.

At the closing, the company paid a cash purchase price of ~$270M, using a combination of cash-on-hand and borrowings under its existing credit facility.

Now read:

for full text news in your inbox



https://ift.tt/2CTwdnD

Comments

Popular posts from this blog

180+ chief medical officers to know | 2025

Primary Care - North Greece Internal Medicine & Pediatrics

Screening and Testing for Hepatitis B Virus Infection ...